Archives for September 21st, 2018
Biopharmaceutical company fined for misleading investors
Custom Synthesis, BOULDER, Colo. – A Colorado-based biopharmaceutical company has been penalized more than $20 million for misleading investors about the efficacy of a lung...
EU approves fifth copy of AbbVie’s $18 bln drug Humira
Custom Synthesis, Europe has approved a fifth copy of AbbVie’s $18-billion-a-year biologic drug Humira – the world’s best-selling prescription medicine – ramping up competition among...
Australian Competition and Consumer Commission clears Arrow and Apotex merger
Custom Synthesis, Strides Pharma Science Thursday said the Australian Competition and Consumer Commission (ACCC) has decided not to oppose the merger of generic pharma companies...